Skin Cancer News
A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.
Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.
The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.
People who elect to undergo sunless tanning tend to continue behaviors that could increase their risk of skin cancer.
The use of multiple sun protection measures was defined as the use of 2 or more of these measures more than 50% of the time when the individual was outdoors.
According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.
The FDA based their approval on findings from the phase 3 COLUMBUS study, in which researchers randomly assigned patients with BRAF V600-mutant melanoma to receive encorafenib plus binimetinib, encorafenib, or vemurafenib.
Results from a small study show that PD-1 inhibitors could work synergistically with radiosurgery to promote slightly longer survival times.
If approved, the new indication could mean pembrolizumab could be used for patients with melanoma.
When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.
Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
The FDA based its approval on the results of the phase 3 COMBI-AD study.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
Improvement in RFS was seen regardless of PD-L1 status.
Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.
One death possibly related to treatment was, however, noted in the combination group.
Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.
A 75% reduction in SCC risk was observed among patients in the fluorouracil arm vs the placebo-arm.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities